Skip to main content

Box 2 Key questions about exosomes-based biomarker

From: A review on exosomes application in clinical trials: perspective, questions, and challenges

Do preclinical results relevant to clinical trial findings?
Does cargo heterogeneity of exosomes cause bias in results?
Because the exosome populations expressed from single cells are heterogeneous, the content concentrations are expected to exist in a range and not at a set standard
What is/are a common/s biomarker for a range of diseases?
What is the contribution of genetics to different outcomes? In other words, Do racial factors correlate with the type of exosomal cargo at the same pathological condition?
Do exosomes contain biomolecules or properties that protect their cargo from degradation?
How do such conditions affect the loading mechanism of exosomes?